Bucharest

The trials here

What the 10 trials at this site are about, from their registry records.

Conditions

• Coronary artery disease3 trials
• Stroke3 trials
• Familial hypercholesterolaemia2 trials
• Multiple sclerosis2 trials
• Asthma1 trial
• Childhood cancers1 trial
• Chronic myeloid leukaemia1 trial
• High blood pressure1 trial
• Pulmonary arterial hypertension1 trial
• Rheumatoid arthritis1 trial

Phase

• Phase 36 trials
• Phase 11 trial
• Phase 1/21 trial
• Phase 41 trial

Status

• Active, not recruiting4 trials
• Completed3 trials
• Recruiting3 trials

Lead sponsor

• Novartis Pharmaceuticals10 trials

Running trials

• Recruiting

  A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.

  NCT05776927· Phase 3· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Active, not recruiting

  An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

  NCT07517263· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

  NCT07225504· Phase 3· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Active, not recruiting

  An Ascending Dose Study of PIT565 in Participants With Rheumatoid Arthritis

  NCT07029555· Phase 1· Novartis Pharmaceuticals· Source

• Recruiting

  A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

  NCT06649110· Phase 1/2· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

• Active, not recruiting

  A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

  NCT05739383· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

  NCT05030428· Phase 3· Novartis Pharmaceuticals· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Asthma1 recruiting
• High blood pressure1 recruiting
• Multiple sclerosis1 recruiting
• Pulmonary arterial hypertension1 recruiting

Closed trials

• Completed

  Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

  NCT04023552· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator

  NCT01742299· Phase 4· Novartis Pharmaceuticals· Source

• Completed

  The Gilenya Pregnancy Registry

  NCT01285479· Novartis Pharmaceuticals· Source